Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
NCT: NCT06420245 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot ulcers. The study aims to determine the incidence of complete wound closure at the end of 12 weeks of treatment. Researchers will compare the outcomes between a group of people treated with standard wound care and another group treated with standard wound care in addition to the amniotic membrane allograft to see if the amniotic membrane allograft improves wound healing. During the study, participants will visit their doctor weekly over a 12 week period, which is standard for diabetic foot ulcer treatment procedures, and fill out a questionnaire measuring quality of life.
Frequently Asked Questions
What is Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management?
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management is a clinical trial registered under NCT06420245. Current status: RECRUITING.
What is the status of NCT06420245?
The current status of NCT06420245 (Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management) is: RECRUITING.
When did Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management start?
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management started on 2025-12-30.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.